At the time of writing, NewAmsterdam Pharma Company NV [NAMS] stock is trading at $21.54, down -2.18%. An important factor to consider is whether the stock is rising or falling in short-term value. The NAMS shares have gain 8.51% over the last week, with a monthly amount drifted -1.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on June 17, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $42. Previously, Stifel started tracking the stock with Buy rating on June 10, 2025, and set its price target to $44. On June 04, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $42 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $48 on December 30, 2024. TD Cowen initiated its recommendation with a Buy. Scotiabank started tracking with a Sector Outperform rating for this stock on March 14, 2024, and assigned it a price target of $35. In a note dated January 18, 2024, Guggenheim initiated an Buy rating and provided a target price of $30 on this stock.
For the past year, the stock price of NewAmsterdam Pharma Company NV fluctuated between $14.06 and $27.29. Currently, Wall Street analysts expect the stock to reach $41 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $21.54 at the most recent close of the market. An investor can expect a potential return of 90.34% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
According to NewAmsterdam Pharma Company NV [NASDAQ:NAMS], the company’s sales were 47.14M for trailing twelve months, which represents an 112.56% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.02%, Pretax Profit Margin comes in at -3.97%, and Net Profit Margin reading is -3.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.33 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.15 points at the first support level, and at 20.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.03, and for the 2nd resistance point, it is at 22.52.
Ratios To Look Out For
It is important to note that NewAmsterdam Pharma Company NV [NASDAQ:NAMS] has a current ratio of 19.98. On the other hand, the Quick Ratio is 19.98, and the Cash Ratio is 18.29. Considering the valuation of this stock, the price to sales ratio is 51.30, the price to book ratio is 3.11.
Transactions by insiders
Recent insider trading involved Topper James N, Director, that happened on Jun 24 ’25 when 2520.0 shares were purchased. Director, Topper James N completed a deal on Jun 25 ’25 to buy 1260.0 shares. Meanwhile, Chief Operating Officer Kling Douglas F sold 100000.0 shares on Jun 16 ’25.
